Vor Biopharma Inc. (VOR) intrinsic value & 10-year financials
Vor Biopharma Inc. (VOR) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $18.03
- Market cap
- $178.0M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -88.7%
- Free cash flow (FY2025)
- -$143.7M
VOR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$696.0M | -$70.50 | -$143.7M | — | 269.9% |
| FY2024 | — | -$116.9M | -$1.70 | -$99.9M | — | -120.8% |
| FY2023 | — | -$117.9M | -$1.75 | -$101.4M | — | -62.1% |
| FY2022 | — | -$92.1M | -$2.33 | -$93.6M | — | -54.0% |
| FY2021 | — | -$68.9M | -$2.10 | -$73.0M | — | -613.5% |
| FY2020 | — | -$43.3M | — | -$40.5M | — | 48.1% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Vor Biopharma Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Vor Biopharma Inc. has historically struggled to out-earn its cost of capital, averaging just -32.0% ROIC.
Vor Biopharma Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Vor Biopharma Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.